Sökning: onr:"swepub:oai:DiVA.org:kth-206264" >
Individually dosed ...
Individually dosed omalizumab : an effective treatment for severe peanut allergy
-
- Brandstrom, J. (författare)
- Karolinska Institutet
-
- Vetander, M. (författare)
- Karolinska Institutet
-
- Lilja, G. (författare)
- Karolinska Institutet
-
visa fler...
-
- Johansson, S. G. O. (författare)
- Karolinska Institutet
-
Sundqvist, A. -C (författare)
-
- Kalm, Frida (författare)
- KTH,Proteomik och nanobioteknologi,Karolinska Univ Hosp, Sweden
-
- Nilsson, C. (författare)
- Karolinska Institutet
-
- Nopp, A. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2017-01-10
- 2017
- Engelska.
-
Ingår i: Clinical and Experimental Allergy. - : WILEY. - 0954-7894 .- 1365-2222. ; 47:4, s. 540-550
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Treatment with omalizumab has shown a positive effect on food allergies, but no dosages are established. Basophil allergen threshold sensitivity (CD-sens) can be used to objectively measure omalizumab treatment efficacy and correlates with the outcome of double-blind placebo-controlled food challenge to peanut. Objective To evaluate whether individualized omalizumab treatment monitored by CD-sens could be an effective intervention for suppression of allergic reactions to peanut. Methods Severely peanut allergic adolescents (n = 23) were treated with omalizumab for 8 weeks, and CD-sens was analysed before and after. Based on whether CD-sens was suppressed after 8 weeks, the patients either were subject to a peanut challenge or received eight more weeks with increased dose of omalizumab, followed by peanut challenge or another 8-week cycle of omalizumab. IgE and IgE-antibodies to peanut and its components were analysed before treatment. Results After individualized omalizumab treatment (8-24 weeks), all patients continued with an open peanut challenge with no (n = 18) or mild (n = 5) objective allergic symptoms. Patients (n = 15) needing an elevated omalizumab dose (ED) to suppress CD-sens had significantly higher CD-sens values at baseline 1.49 (0.44-20.5) compared to those (n = 8) who managed with normal dose (ND) 0.32 (0.24-5.5) (P < 0.01). Median ratios for Ara h 2 IgE-ab/IgE were significantly higher in the ED group (17%) compared to the ND group (11%). Conclusions and Clinical Relevance Individually dosed omalizumab, monitored by CD-sens, is an effective and safe treatment for severe peanut allergy. The ratio of IgE-ab to storage protein Ara h 2/IgE as well as CD-sens to peanut may predict the need of a higher omalizumab dose.
Ämnesord
- NATURVETENSKAP -- Biologi -- Immunologi (hsv//swe)
- NATURAL SCIENCES -- Biological Sciences -- Immunology (hsv//eng)
Nyckelord
- basophil
- food allergy
- IgE
- CD-sens
- omalizumab (or anti-IgE)
- immunotherapy and tolerance induction
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas